1. Home
  2. HUMA vs ALT Comparison

HUMA vs ALT Comparison

Compare HUMA & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HUMA
  • ALT
  • Stock Information
  • Founded
  • HUMA 2004
  • ALT 1997
  • Country
  • HUMA United States
  • ALT United States
  • Employees
  • HUMA N/A
  • ALT N/A
  • Industry
  • HUMA Biotechnology: Pharmaceutical Preparations
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • HUMA Health Care
  • ALT Health Care
  • Exchange
  • HUMA Nasdaq
  • ALT Nasdaq
  • Market Cap
  • HUMA 221.8M
  • ALT 472.3M
  • IPO Year
  • HUMA N/A
  • ALT N/A
  • Fundamental
  • Price
  • HUMA $1.21
  • ALT $5.80
  • Analyst Decision
  • HUMA Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • HUMA 6
  • ALT 7
  • Target Price
  • HUMA $14.60
  • ALT $21.00
  • AVG Volume (30 Days)
  • HUMA 2.9M
  • ALT 2.0M
  • Earning Date
  • HUMA 05-20-2025
  • ALT 05-13-2025
  • Dividend Yield
  • HUMA N/A
  • ALT N/A
  • EPS Growth
  • HUMA N/A
  • ALT N/A
  • EPS
  • HUMA N/A
  • ALT N/A
  • Revenue
  • HUMA N/A
  • ALT $20,000.00
  • Revenue This Year
  • HUMA N/A
  • ALT N/A
  • Revenue Next Year
  • HUMA $1,178.20
  • ALT N/A
  • P/E Ratio
  • HUMA N/A
  • ALT N/A
  • Revenue Growth
  • HUMA N/A
  • ALT N/A
  • 52 Week Low
  • HUMA $1.15
  • ALT $3.55
  • 52 Week High
  • HUMA $9.97
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • HUMA 30.35
  • ALT 60.47
  • Support Level
  • HUMA $1.35
  • ALT $4.95
  • Resistance Level
  • HUMA $1.48
  • ALT $6.05
  • Average True Range (ATR)
  • HUMA 0.10
  • ALT 0.37
  • MACD
  • HUMA 0.03
  • ALT 0.11
  • Stochastic Oscillator
  • HUMA 4.26
  • ALT 85.17

About HUMA Humacyte Inc.

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Share on Social Networks: